Cancer

Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome

TNX-2900 is a proprietary magnesium-potentiated formulation of intranasal oxytocin, a naturally occurring hormone that reduces appetite and eating Prader Willi…

4 months ago

Starton Therapeutics to Present at Upcoming MedInvest and Needham Conferences

PARAMUS, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc., (“Starton” or the “Company”), a clinical-stage biotechnology company focused…

4 months ago

Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update

Major achievements in 2023 lay the foundation for key upcoming milestonesSOLANA BEACH, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Artelo…

4 months ago

Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic

Plus’ CSF-01 cancer cell enumeration test is a sensitive and specific diagnostic test for the presence of adenocarcinoma and melanoma…

4 months ago

GENE to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised Healthcare

MELBOURNE, Australia, March 25, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ:GENE, “Company”, “GENE”), a global leader in guideline-driven genomics-based…

4 months ago

Defence Completes 2nd Tranche of Financing

Vancouver, British Columbia--(Newsfile Corp. - March 22, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or…

4 months ago

GE HealthCare to Feature Latest Technologies in Interventional Radiology Focused on Precision Care at SIR 2024

Multi-modality showcase brings hands-on experience to care delivery for a wide range of vascular diseases and health conditions Scientific studies…

4 months ago

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

OCALA, Fla., March 22, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the…

4 months ago

Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology…

4 months ago

Angle PLC Announces Parsortix at European Breast Cancer Conference

PARSORTIX SYSTEM AND ASSAYS BEING SHOWCASED AT A LEADING EUROPEAN BREAST CANCER CONFERENCEANGLE presenting two posters highlighting the utility of…

4 months ago